Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | CA9 | Q16790 | 6/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | HTR2B | P41595 | 4/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134493 | 1.00 | CYP1A2 (0.47) | CYP1A2TSHRCYP2C19MAPTPKM | |
| SCHEMBL30637024 | 1.00 | CYP1A2 (0.47) | CYP1A2TSHRCYP2C19MAPTPKM | |
| SCHEMBL20074011 | 0.86 | CXCR2 (0.41) | CYP1A2TSHRCYP2C19MAPTPKM | |
| SCHEMBL20065135 | 0.86 | CXCR2 (0.41) | CYP1A2TSHRCYP2C19MAPTPKM | |
| SCHEMBL6082005 | 0.85 | TSHR (0.49) | CYP1A2TSHRCYP2C19MAPTPKM | |
| SCHEMBL27380324 | 0.84 | CA1 (0.44) | CYP1A2TSHRCYP2C19MAPTPKM | |
| SCHEMBL23020812 | 0.84 | TSHR (0.48) | CYP1A2TSHRCYP2C19MAPTPKM | |
| SCHEMBL25295225 | 0.83 | DHODH (0.42) | MAPTPKMCA1CA2CA9 | |
| SCHEMBL30509989 | 0.83 | DHODH (0.42) | MAPTPKMCA1CA2CA9 | |
| SCHEMBL30636993 | 0.83 | HTR2A (0.49) | CYP1A2TSHRCYP2C19MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250230-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-07 | — | — | US | disclosed |
| EP-4508027-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023199091-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023125846-A1 | COMPOUND FOR PREVENTING AND TREATING CORONAVIRUS INFECTION, CONJUGATE THEREOF AND METHOD THEREFOR | 苏州爱科百发生物医药技术有限公司 | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250230-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NPY2R | CYP1A2 285/4885TSHR 337/4885CYP2C19 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.